664 related articles for article (PubMed ID: 28869890)
21. Association of concurrent hepatitis B surface antigen and antibody to hepatitis B surface antigen with hepatocellular carcinoma in chronic hepatitis B virus infection.
Jang JS; Kim HS; Kim HJ; Shin WG; Kim KH; Lee JH; Kim HY; Kim DJ; Lee MS; Park CK; Jeong BH; Kim YS; Jang MK
J Med Virol; 2009 Sep; 81(9):1531-8. PubMed ID: 19623669
[TBL] [Abstract][Full Text] [Related]
22. Long-term follow-up of children with postnatal immunoprophylaxis failure who were infected with hepatitis B virus surface antigen gene mutant.
Hsu HY; Chang MH; Ni YH; Jeng YM; Chiang CL; Chen HL; Wu JF; Chen PJ
J Infect Dis; 2013 Apr; 207(7):1047-57. PubMed ID: 23300165
[TBL] [Abstract][Full Text] [Related]
23. Kinetics of hepatitis B surface and envelope antigen and prediction of treatment response to tenofovir in antiretroviral-experienced HIV-hepatitis B virus-infected patients.
Maylin S; Boyd A; Lavocat F; Gozlan J; Lascoux-Combe C; Miailhes P; Lassel L; Delaugerre C; Girard PM; Zoulim F; Lacombe K
AIDS; 2012 May; 26(8):939-49. PubMed ID: 22333748
[TBL] [Abstract][Full Text] [Related]
24. Higher rates of HBsAg clearance with tenofovir-containing therapy in HBV/HIV co-infection.
Gantner P; Cotte L; Allavena C; Bani-Sadr F; Huleux T; Duvivier C; Valantin MA; Jacomet C; Joly V; Chéret A; Pugliese P; Delobel P; Cabié A; Rey D;
PLoS One; 2019; 14(4):e0215464. PubMed ID: 30998789
[TBL] [Abstract][Full Text] [Related]
25. Hepatitis B serological markers and plasma DNA concentrations.
Price H; Dunn D; Zachary T; Vudriko T; Chirara M; Kityo C; Munderi P; Spyer M; Hakim J; Gilks C; Kaleebu P; Pillay D; Gilson R;
AIDS; 2017 May; 31(8):1109-1117. PubMed ID: 28328795
[TBL] [Abstract][Full Text] [Related]
26. Hepatitis B and hepatitis C virus infections among antiretroviral-naive and -experienced HIV co-infected adults.
Manyazewal T; Sisay Z; Biadgilign S; Abegaz WE
J Med Microbiol; 2014 May; 63(Pt 5):742-747. PubMed ID: 24757219
[TBL] [Abstract][Full Text] [Related]
27. [Persistence of hepatitis B virus in children after interferon-alpha therapy despite the seroconversion in HBsAg/anti-HBs system].
Gregorek H; Dzierzanowska-Fangrat K; Woynarowski M; Jóźwiak P; Witkowska-Vogtt E; Wojda U; Syczewska M; Socha J; Madalińiski K
Przegl Epidemiol; 2005; 59(3):641-9. PubMed ID: 16433306
[TBL] [Abstract][Full Text] [Related]
28. Mutation in the S gene of hepatitis B virus and anti-HBs subtype-nonspecificity contributed to the co-existence of HBsAg and anti-HBs in patients with chronic hepatitis B virus infection.
Fu X; Chen J; Chen H; Lin J; Xun Z; Li S; Liu C; Zeng Y; Chen T; Yang B; Ou Q
J Med Virol; 2017 Aug; 89(8):1419-1426. PubMed ID: 28198078
[TBL] [Abstract][Full Text] [Related]
29. Predicting HBsAg clearance in genotype A chronic hepatitis B using HBsAg epitope profiling: A biomarker for functional cure.
Walsh R; Hammond R; Yuen L; Deerain J; O'Donnell T; Leary T; Cloherty G; Gaggar A; Kitrinos K; Subramanian M; Wong D; Locarnini S
Liver Int; 2019 Nov; 39(11):2066-2076. PubMed ID: 31379058
[TBL] [Abstract][Full Text] [Related]
30. Evolution of hepatitis B serological markers in HIV-infected patients receiving highly active antiretroviral therapy.
Sheng WH; Kao JH; Chen PJ; Huang LM; Chang SY; Sun HY; Hung CC; Chen MY; Chang SC
Clin Infect Dis; 2007 Nov; 45(9):1221-9. PubMed ID: 17918088
[TBL] [Abstract][Full Text] [Related]
31. Coexistence of hepatitis B surface antigen (HBsAg) and heterologous subtype-specific antibodies to HBsAg among patients with chronic hepatitis B virus infection.
Zhang JM; Xu Y; Wang XY; Yin YK; Wu XH; Weng XH; Lu M
Clin Infect Dis; 2007 May; 44(9):1161-9. PubMed ID: 17407033
[TBL] [Abstract][Full Text] [Related]
32. Seroprevalence of Hepatitis B Among HIV-infected Children and Adolescents Receiving Antiretroviral Therapy in the TREAT Asia Pediatric HIV Observational Database.
Aurpibul L; Kariminia A; Vibol U; Fong MS; Le ON; Hansudewechakul R; Bunupuradah T; Kurniati N; Chokephaibulkit K; Kumarasamy N; Wati DK; Yusoff NKN; Razali KAM; Nallusamy RA; Sohn AH; Lumbiganon P;
Pediatr Infect Dis J; 2018 Aug; 37(8):788-793. PubMed ID: 29846357
[TBL] [Abstract][Full Text] [Related]
33. Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy.
Lan JL; Chen YM; Hsieh TY; Chen YH; Hsieh CW; Chen DY; Yang SS
Ann Rheum Dis; 2011 Oct; 70(10):1719-25. PubMed ID: 21719446
[TBL] [Abstract][Full Text] [Related]
34. Incidence and determinants of spontaneous hepatitis B surface antigen seroclearance and seroconversion in hepatitis B e antigen-negative chronic infection patients: A population-based prospective cohort.
Zhu L; Zhai X; Wang Q; Jiang J; Peng H; Song C; Ge Z; Qian J; Zhou M; Zhou Y; Xu J; Liu H; Hang D; Hu Z; Shen H; Zhu F
J Viral Hepat; 2018 Dec; 25(12):1588-1598. PubMed ID: 30112835
[TBL] [Abstract][Full Text] [Related]
35. Hepatitis B virus prevalence and vaccine response in HIV-infected children and adolescents on combination antiretroviral therapy in Kigali, Rwanda.
Mutwa PR; Boer KR; Rusine JB; Muganga N; Tuyishimire D; Reiss P; Lange JM; Geelen SP
Pediatr Infect Dis J; 2013 Mar; 32(3):246-51. PubMed ID: 22976050
[TBL] [Abstract][Full Text] [Related]
36. Improved immune status corresponds with long-term decline of quantitative serum hepatitis B surface antigen in HBV/HIV co-infected patients.
Arendt E; Jaroszewicz J; Rockstroh J; Meyer-Olson D; Zacher BJ; Mederacke I; Manns MP; Wedemeyer H; Cornberg M; Wursthorn K
Viral Immunol; 2012 Dec; 25(6):442-7. PubMed ID: 23131018
[TBL] [Abstract][Full Text] [Related]
37. High rates of HBsAg seroconversion in HBeAg-positive chronic hepatitis B patients responding to interferon: a long-term follow-up study.
Moucari R; Korevaar A; Lada O; Martinot-Peignoux M; Boyer N; Mackiewicz V; Dauvergne A; Cardoso AC; Asselah T; Nicolas-Chanoine MH; Vidaud M; Valla D; Bedossa P; Marcellin P
J Hepatol; 2009 Jun; 50(6):1084-92. PubMed ID: 19376603
[TBL] [Abstract][Full Text] [Related]
38. Failure of therapeutic vaccination using hepatitis B surface antigen vaccine in the immunotolerant phase of children with chronic hepatitis B infection.
Dikici B; Bosnak M; Ucmak H; Dagli A; Ece A; Haspolat K
J Gastroenterol Hepatol; 2003 Feb; 18(2):218-22. PubMed ID: 12542609
[TBL] [Abstract][Full Text] [Related]
39. Occult hepatitis B virus infection in ART-naive HIV-infected patients seen at a tertiary care centre in north India.
Gupta S; Singh S
BMC Infect Dis; 2010 Mar; 10():53. PubMed ID: 20205948
[TBL] [Abstract][Full Text] [Related]
40. Elimination of hepatitis B virus surface antigen and appearance of neutralizing antibodies in chronically infected patients without viral clearance.
Zhang ZH; Li L; Zhao XP; Glebe D; Bremer CM; Zhang ZM; Tian YJ; Wang BJ; Yang Y; Gerlich W; Roggendorf M; Li X; Lu M; Yang DL
J Viral Hepat; 2011 Jun; 18(6):424-33. PubMed ID: 20819150
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
